Enveric Biosciences (ENVB) Stock Surges Over 160% After Trump Executive Order on Psychedelics

TLDR

• President Trump signed an executive order directing health regulators to fast-track the review of psychedelic drugs, triggering a broad sector rally.
• ENVB surged more than 160% in trading, making it one of the biggest movers in the psychedelic biotech space.
• Trump also committed $50 million to ibogaine research, a Schedule I compound being studied for PTSD treatment.
• Compass Pathways (CMPS) rose 26.1%, AtaiBeckley (ATAI) gained 28.1%, and GH Research (GHRS) climbed nearly 20%.
• RBC analyst Brian Abrahams called the executive order “a substantial step towards diminishing regulatory risk” for the sector.

Psychedelic biotech stocks got a jolt Monday after President Trump signed an executive order over the weekend instructing federal health regulators to speed up the review process for psychedelic-based treatments. Enveric Biosciences (ENVB) led the charge, finishing the session up more than 160% — a jaw-dropping move for a stock with a market cap of just $3.43 million.

Enveric Biosciences, Inc., ENVB

The executive order didn’t single out any one company. It was a broad directive to the FDA and related agencies to cut red tape around psychedelic drug approvals. That was enough to send nearly every name in the space flying.

AtaiBeckley (ATAI) jumped 28.1% in premarket. Compass Pathways (CMPS) added 26.1%. Definium Therapeutics (DFTX) gained 14.6%. GH Research (GHRS) was up 19.7%. The rally spread wide and fast.

Trump’s $50M Ibogaine Push

Beyond the executive order, Trump pledged $50 million toward ibogaine research. Ibogaine is a psychoactive compound derived from an African plant and currently sits on the Schedule I list in the U.S. — meaning it has no federally recognized medical use.

The investment signals a real shift in how the administration is thinking about mental health, particularly post-traumatic stress disorder. Ibogaine has shown promise in early research for PTSD, especially among veterans.

ENVB’s rally came with added context. Just days earlier, the company closed a $5 million private placement — a raise that was more than the company’s entire market cap at the time. It sold 2,222,223 shares at $2.25 each, along with two series of warrants priced at $2.00 per share.

ENVB’s Pipeline and IP Moves

The company’s lead drug candidate, EB-003, targets 5-HT2A and 5-HT1B receptors and is being developed for psychiatric and neurological conditions. New mechanistic data released recently showed EB-003 activates dual signaling pathways linked to antidepressant and anxiolytic effects.

ENVB also recently received a U.S. patent covering its EVM301 molecules, which include EB-003, along with Canadian trademark registrations for five of its marks including “Enveric” and “Next Generation Mental Health.”

If both warrant series from the private placement are fully exercised, the company could bring in an additional $8.9 million in gross proceeds.

The stock’s move Monday — over 160% — reflected both the macro tailwind from the executive order and the recent fundraising that gave the company a longer runway heading into that moment.

The post Enveric Biosciences (ENVB) Stock Surges Over 160% After Trump Executive Order on Psychedelics appeared first on CoinCentral.